Table 2.

Main clinical and laboratory parameters at start and end of treatment period

OctreotidePlaceboP for Delta %
Baseline12 moDelta %Baseline12 moDelta %
Creatinine, mg/dl1.1 (0.43)1.1 (0.47)0.0 (0.12)1.1 (0.52)1.2 (0.62)0.05 (0.12)0.56
Iothalamate GFRa, ml/min per 1.73 m268.1 (26.53)64.6 (25.66)−5.1 (15.46)70.8 (28.08)65.7 (26.40)−7.2 (13.21)0.98
Aspartate aminotransferase, U/L32.5 (13.77)29.9 (8.61)−2.4 (23.6628.6 (7.93)29.1 (6.11)5.2 (17.93)0.23
Albumin, g/dl4.3 (0.18)4.3 (0.20)0.4 (4.47)4.4 (0.19)4.4 (0.19)1.1 (4.54)0.64
Bilirubin, μmol/L0.6 (0.26)0.6 (0.24)17.5 (61.72)1.0 (1.52)0.7 (0.40)−3.7 (34.09)0.98
Alkaline phosphatase, U/L92.5 (47.78)99.0 (49.21)9.8 (24.38)107.5 (55.91)101.4 (36.20)−1.0 (14.91)0.29
Prothrombin time, INR9.6 (0.71)10.4 (0.66)7.5 (4.98)10.9 (5.22)10.5 (1.59)2.8 (15.61)0.83
Sodium, mEq/L139.0 (3.05)138.0 (3.30)−0.7 (2.67)139.2 (2.58)139.2 (2.08)0.0 (1.86)0.12
Potassium, mEq/L4.5 (0.46)4.4 (0.35)−1.5 (8.61)4.3 (0.44)4.4 (0.43)3.2 (15.85)0.48
Blood glucose, mg/dl93.4 (11.22)102.4 (11.54)10.2 (11.25)93.6 (7.81)95.3 (8.01)2.0 (7.10)0.02b
BUN, mg/dl19.0 (7.23)19.0 (7.37)0.5 (19.72)18.5 (7.66)22.1 (10.50)18.2 (21.40)0.03b
Hemoglobin, g/dl12.8 (1.24)12.6 (1.38)−1.1 (5.31)12.9 (0.97)12.7 (1.14)−1.4 (5.84)0.74
Liver volume, ml5907.7 (2915.0)5557.1 (2659.4)−5.0 (6.77)5373.9 (3565.4)5360.6 (3330.9)0.9 (8.33)0.048b
Kidney volume, mla1142.9 (826.9)1128.5 (796.0)0.25 (7.53)803.0 (269.1)873.5 (306.2)8.61 (10.07)0.045b
  • Data shown as mean (SD). BUN, blood urea nitrogen.

  • aKidney volume/GFR: four transplant patients, eight ADPLD patients, and one patient with missing values were removed from this analysis.

  • bP < 0.05 octreotide versus placebo group.